Baseline characteristics of MMSC plus conventional therapy treated patients and conventional therapy treated patients (at onset of septic shock prior to randomization).

Table 1: Baseline characteristics of MMSC plus conventional therapy treated patients and conventional therapy treated patients (at onset of septic shock prior to randomization).

Parameter	MMSCs + Conventional therapy (n = 15)	Conventional therapy (n = 15)
Time interval from the onset of septic shock to randomization (hours), Me (IQR)	5 (4-7)	5.5 (3-8)
Age (years) Me (ranges)	40 (30-75)	47 (33-81)
Male/Female (n)	6/9	7/8
Underlying diseases
Acute myeloid leukemia	5	4
Myelodysplastic syndrome	1	1
Non-Hodgkin's lymphoma	6	5
Multiple myeloma	1	3
Renal transplantation	1	1
Hodgkin's lymphoma	0	1
Acute lymphoblastic leukemia	1	0
Number of the patients received
Chemotherapy	11	12
Immunosuppressive therapy	1	2
HSCT	3	1
Time from the end of the chemotherapy to randomization (days), Me (ranges)	7 (1-64)	8 (0-21)
APACHE II score, Me (IQR)	33.5 (26.3-36.0)	34.0 (27-36)
SOFA score, Me (IQR)	16.0 (15.0-17.0)	16.5 (15.0-17.8)
Noradrenaline doses, Me (IQR)	1.0 (IQR 0.5-1.75)	1.4 (IQR 0.6-1.9)
Serum lactate concentrations, mmol/l, Me (IQR), mmol/l	3.5 (2.9-4.5)	3.5 (2.5-4.2)
Mechanically ventilated patients	8	4
Patients required renal replacement therapy	5	4
Positive blood cultures	• Pseudomonas aeruginosa + Staphylococcus haemolyticus [1], • Pseudomonas aeruginosa + Enterococcus faecium [1], • Escherichia coli [2], • Klebsiella pneumoniae [https://www.ncbi.nlm.nih.gov/pubmed/17416739], • Klebsiella oxytoca [1], • Pseudomonas aeruginosa + Escherichia coli [1] • Escherichia coli [1], • Sphingobacterium multivorum [1] • Stenotrophomonas maltophilia + Klebsiella pneumoniae [1], • Candida albicans [1]	• Acinetobacter baumannii + Klebsiella pneumoniae [2] • Klebsiella pneumoniae + Enterococcus faecium [1] • Pseudomonas aeruginosa [1] • Klebsiella pneumoniae [1] • Enterococcus faecium [2], • Candida krusei [1] • Candida tropicalis [1] • Acromonium [1]